Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RNAZ vs FEMY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RNAZ Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 5–2 Matrix Metrics)

RNAZ Overall Winner 6-Pillar Tally: RNAZ 2 – 2 FEMY (2 Tie) Matrix Metrics: RNAZ 5 – 2 FEMY

As of Nov 16, 2026, TransCode Therapeutics, Inc. (RNAZ) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). RNAZ carries a Unified Composite Score of 50.3/100 (HOLD) at $1.35 (N/M Forward P/E, 0.0% operating margin), whereas FEMY carries 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin).

  • Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. RNAZ 50.3/100 HOLD), RNAZ captures the overall institutional head-to-head verdict (5–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -763.9% operating margin) and revenue trajectory (+0.0% vs. -18.9% YoY).
  • Technical & Structure Timing Caution: RNAZ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.1); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RNAZ vs FEMY
RNAZ NASDAQ Head-to-Head Winner
TransCode Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$1.35
+2.27% 1D
Market Cap $22.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.96β · 63% Vol
Unified Composite Score
50.3 / 100 HOLD
Tech 53.0 Fund 48.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.4%), weak momentum, RSI 34
RSI-14: 34.1 · SMA20: $1.57 · SMA50: $1.65
FEMY NASDAQ
Femasys Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$1.28
-9.86% 1D
Market Cap $11.9M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 4.01β · 72% Vol
Unified Composite Score
52.6 / 100 HOLD
Tech 61.0 Fund 62.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.5%), weak momentum, RSI 35
RSI-14: 34.6 · SMA20: $1.43 · SMA50: $1.92

6-Pillar Scorecard Institutional Category Breakdown (RNAZ 2 – 2 FEMY)

Columns: Metric · RNAZ · FEMY
1. Valuation Multiples FEMY
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 4.9x
2. Growth & Scale RNAZ
Revenue Growth (YoY) +0.0% -18.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $2.3M
Market Cap $22.3M $11.9M
3. Profitability & Quality RNAZ
Gross Margin N/A 60.9%
Operating Margin 0.0% -763.9%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -59.3% -425.0%
4. Balance Sheet & Cash Flow FEMY
Cash Generation (TTM) -$21M -$19M
Cash Flow Margin N/A N/A
Net Cash / Leverage -59.3% ROE -$658,045 Net Debt (0.65x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RNAZ (5) vs FEMY (2)
Institutional Metric RNAZ FEMY Criterion Row Edge
Market Capitalization
Scale
$22.3M $11.9M Larger Scale RNAZ
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -18.9% Higher Growth RNAZ
Operating Margin (TTM)
Profitability
0.0% -763.9% Higher Margin RNAZ
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-59.3% -425.0% Higher ROE RNAZ
52-Week Range Position
Momentum
0% ($1–$13) 17% ($0–$6) Stronger Trend FEMY
Beta / 30D Volatility
Risk Regime
0.96β · 63% Vol 4.01β · 72% Vol Lower Realized Risk RNAZ
Unified Institutional Score
Composite Signal
50.3 / 100 (HOLD) 52.6 / 100 (HOLD) Higher Composite FEMY
Trailing 12M Revenue (USD)
Operating Scale
N/A $2.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 60.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 4.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M (-59.3% ROE) -$19M (-$658,045 Net Debt (0.65x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RNAZ +1.83 pp
RNAZ: -20.59% · FEMY: -22.42%
3M Horizon FEMY +16.51 pp
RNAZ: -58.33% · FEMY: -41.82%
6M Horizon FEMY +338.5 pp
RNAZ: -79.55% · FEMY: +258.95%
1Y Horizon FEMY +138.75 pp
RNAZ: -83.97% · FEMY: +54.78%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RNAZ vs FEMY. Trailing 12-month operating profitability (RNAZ 0.0% vs FEMY -763.9%) and valuation multiples (RNAZ N/M vs FEMY N/M Forward P/E) are benchmarked directly in Pillar 4 below.

RNAZ ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-59.3% · N/M
FEMY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.3M
Gross Margin60.9%
Op. Margin-763.9%
ROE / Fwd P/E-425.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RNAZ UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RNAZ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FEMY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FEMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RNAZ Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $22.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FEMY Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $11.9M market capitalization and -763.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RNAZ vs FEMY Key Questions & Quantitative Answers

As of Nov 16, 2026, TransCode Therapeutics, Inc. (RNAZ) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). RNAZ carries a Unified Composite Score of 50.3/100 (HOLD) at $1.35 (N/M Forward P/E, 0.0% operating margin), whereas FEMY carries 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin). Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. RNAZ 50.3/100 HOLD), RNAZ captures the overall institutional head-to-head verdict (5–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -763.9% operating margin) and revenue trajectory (+0.0% vs. -18.9% YoY). Technical & Structure Timing Caution: RNAZ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.1); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RNAZ leads the Growth & Scale pillar: RNAZ posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with FEMY at -18.9% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (60.9% gross margin, -763.9% operating margin). On trailing 12-month operating scale, RNAZ generates N/A in USD-normalized revenue versus $2.3M for FEMY. In operating R&D and SG&A reinvestment, RNAZ deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FEMY.

FEMY screens cheaper on headline valuation multiples. RNAZ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas FEMY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RNAZ (-59.3% ROE) versus FEMY (-425.0% ROE) capital efficiency.

In options market volatility and institutional positioning, RNAZ carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.96β · 63% Vol realized risk). By comparison, FEMY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.01β · 72% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.